–   Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® –   Q3 2025 operating profit of €11.0 million –   TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 –   Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2025, and provided a busine ...